Phase 4
Completed N=491
Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients
Source: ClinicalTrials.gov NCT00734630 ↗Enrolled (actual)
491
Serious AEs
0.8%
Results posted
Apr 2011
Primary outcomePrimary: Mean Seated Trough Cuff Systolic Blood Pressure (SBP) at Week 12 — -10.1; -7.3 mmHG
Summary
This study will assess blood pressure reduction with nebivolol or placebo in patients taking lisinopril or losartan.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Seated Trough Cuff Systolic Blood Pressure (SBP) at Week 12 |
-10.1; -7.3 | — |
| SECONDARY Mean Seated Trough Cuff Diastolic Blood Pressure (DBP) at Week 12 |
-7.8; -3.5 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female, ambulatory outpatients 18-85 years old at screening
- Have a history of hypertension
- Qualifying laboratory results
Exclusion Criteria
- Severe hypertension, including chronic kidney disease
- Documented congestive heart failure
- Have clinically significant respiratory, liver, or heart disease
- History of stroke, heart attack, or heart surgery in the last 6 months
- Have a history of hypersensitivity to nebivolol or other beta blockers.
Data sourced from ClinicalTrials.gov (NCT00734630). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.